Toxicological considerations of acetylcholinesterase reactivators

Expert Opinion on Drug Metabolism and Toxicology

Volumn 9, Issue 1, 2013, Pages 31-50

  Voicu, Victor ^a,b   Rǎdulescu, Flavian Ştefan ^a   Medvedovici, Andrei ^c  

^a CAROL DAVILA UNIVERSITY OF MEDICINE AND PHARMACY   (Romania)

^b Army Center for Medical Research   (Romania)

^c UNIVERSITY OF BUCHAREST   (Romania)

Author keywords

AChE reactivators; Acute toxicity; Biodistribution; Efficacy; OP intoxication; Oximes; Pharmacokinetics

Indexed keywords

1 (4 CARBAMOYLPYRIDINIO) 1' (2 HYDROXYIMINOMETHYLPYRIDINIO)DIMETHYL ETHER; CHOLINESTERASE REACTIVATOR; NITROGEN; OBIDOXIME; OXIME; PRALIDOXIME; TRIMEDOXIME;

ACUTE TOXICITY; BLOOD PRESSURE; BLURRED VISION; CONCENTRATION LOSS; DIPLOPIA; DIZZINESS; FATIGUE; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARREST; HEART ARRHYTHMIA; HUMAN; HYPOTENSION; INJECTION SITE BURNING; INTOXICATION; LD 50; MUSCLE WEAKNESS; NAUSEA; NONHUMAN; PARESTHESIA; PASSIVE TRANSPORT; PHYSICAL CHEMISTRY; REVIEW; SIDE EFFECT; STOMACH DISCOMFORT; STRUCTURE ACTIVITY RELATION; TACHYCARDIA; VOMITING;

ACETYLCHOLINESTERASE; ANIMALS; CHOLINESTERASE REACTIVATORS; HUMANS; OXIMES; STRUCTURE-ACTIVITY RELATIONSHIP; TISSUE DISTRIBUTION;

EID: 84871256085     PISSN: 17425255     EISSN: 17447607     Source Type: Journal    
DOI: 10.1517/17425255.2013.736489     Document Type: Review

References (128)

1. Koolpe GA, Lovejoy SM, Goff DA, et al. Quaternary salts of 2- [(hydroxyimino)methyl]imidazoles 5. Structure-activity relationships for side-chain nitro-sulfone-, amino-, and aminosulfonyl-substituted analogues for therapy against anticholinesterase intoxication. J Med Chem 1991;34:1368-76
2. Mesic M, Roncevic R, Radic B, et al. Reactivators of acetylcholinesterase inhibited by organophosphorus compounds. Imidazole derivatives V. Acta Pharm 1994;44:145-50 (Pubitemid 24311382)
3. Skrinjaric-Spoljar M, Burger N, Lovric J. Inhibition of acetylcholinesterase by three new pyridinium compounds and their effect on phosphonylation of the enzyme. J Enzyme Inhib 1999;14:331-41 (Pubitemid 29408270)
4. Bregovec I, Maksimovic M, Kilibarda V, et al. Adamantane derivatives as potential reactivators of acetylcholinesterase inhibited by organophosphorous compounds. Acta Pharm 1992;42:251-3 (Pubitemid 23002581)
5. Kuca K, Picha J, Cabal J, et al. Synthesis of the three monopyridinium oximes and evaluation of their potency to reactivate acetylcholinesterase inhibited by nerve agents. J Appl Biomed 2004;2:51-6
6. Picha J, Kuca K, Kivala M, et al. New group of monoquaternary reactivators of the acetylcholinesterase inhibited by nerve agents. J Enzyme Inhib Med Chem 2005;20:233-7 (Pubitemid 41015737)
7. Hampl F, Mazac J, Liska F, et al. Quaternary heteroarenium aldoximes as catalysts for cleavage of phosphate esters. Collect Czech Chem Commun 1995;60:883-93
8. Sikder AK, Ghosh AK, Jaiswal DK. Quaternary salts of 3,3'-bis-pyridinium monooximes: synthesis and biological activity. J Pharm Sci 1993;82:258-61 (Pubitemid 23150405)
9. Acharya J, Gupta AK, Dubey DK, et al. Synthesis and evaluation of novel bis-pyridinium oximes as reactivators of DFP-inhibited acetylcholinesterase. Eur J Med Chem 2009;44:1335-40
10. Acharya J, Rana H, Kaushik MP. Synthesis and in-vitro evaluation of xylene linked carbamoyl bis-pyridinium mono oximes as reactivators of organophosphorus (OP) inhibited electric eel acetylcholinesterase (AChE). Eur J Med Chem 2011;46:3926-33
11. Musilek K, Kuca K, Dohnal V, et al. Two step synthesis of non-symmetric reactivator of acetylcholinesterase. Molecules 2007;12:1755-61
12. Yang GY, Oh KA, Park NJ, et al. New oxime reactivators connected with CH2O (CH2)nOCH2 linker and theirreactivation potency for organophosphorus agents inhibited acetylcholinesterase. Bioorg Med Chem 2007;5:7704-10 (Pubitemid 47575918)
13. Bharate SB, Guo L, Reeves TE, et al. Bisquaternary pyridinium oximes: comparison of in vitro reactivation potency of compounds bearing aliphatic linkers and heteroaromatic linkers for paraoxon-inhibited electric eel and recombinant human acetylcholinesterase. Bioorg Med Chem 2010;18:787-94
14. Cabal J, Kuca K, Kassa J. Specification of the structure of oximes able to reactivate tabun inhibited acetylcholinesterase. Bas Clin Pharmacol Toxicol 2004;95:81-6 (Pubitemid 39310897)
15. Taylor P, Kovarik Z, Reiner E, et al.Acetylcholinesterase: converting a vulnerable target to a template for antidotes and detection of inhibitor exposure. Toxicology 2007;233:70-8 (Pubitemid 46498386)
16. Worek F, Thiermann H, Szinicz L, et al. Kinetic analysis of interactions between human acetylcholinesterase, structurally different organophosphorus compounds and oximes. Biochem Pharmacol 2004;68:2237-48 (Pubitemid 39446151)
17. Maxwell DM, Koplovitz I, Worek F, et al. A structure-activity analysis of the variation in oxime efficacy against nerve agents. Toxicol Appl Pharmacol 2008;231:157-64
18. Luo C, Chambers C, Yang Y, et al. Mechanism for potent reactivation ability of H oximes analyzed by reactivation kinetic studies with cholinesterases from different species. Chem Biol Interact 2010;187:185-90
19. Worek F, Eyer P, Aurbek N, et al. Recent advances in evaluation of oxime efficacy in nerve agent poisoning by in vitro analysis. Toxicol Appl Pharmacol 2007;219:226-34 (Pubitemid 46282867)
20. Worek F, Littig P, Widmann R, et al. Reappraisal of factors for the evaluation of oximes as reactivators of nerve agent-inhibited human acetylcholinesterase. Proceedings of the Seventh International Symposium on Protection against CBW Agents; Stockholm, Sweden; 2001. p. 1-6
21. Lundy PM, Hamilton MG, Sawyer TW, et al. Comparative protective effects of HI-6 and MMB-4 against organophosphorous nerve agent poisoning. Toxicology 2011;285:90-6
22. Kovarik Z, Radíc Z, Berman HA, et al. Acetylcholinesterase active center and gorge conformations analysed by combinatorial mutations and enantiomeric phosphonates. Biochem J 2003;373:33-40 (Pubitemid 36819498)
23. Kovarik Z, Radi'c Z, Berman HA, et al. Mutant cholinesterases possessing enhanced capacity for reactivation of heir phosphonylated conjugates. Biochemistry 2004;43:3222-9 (Pubitemid 38352271)
24. Taylor P, Radic Z. The cholinesterases: from genes to proteins. Annu Rev Pharmacol Toxicol 1994;34:281-320
25. Aurbek N, Thiermann H, Szinicz L, et al. Analysis of inhibition, reactivation and aging kinetics of highly toxic organophosphorus compounds with human and pig acetylcholinesterase. Toxicology 2006;224:91-9
26. Luo C, Chambers C, Pattabiraman N, et al. Y124 at the peripheral anionic site is important for the reactivation of nerve agent-inhibited acetylcholinesterase by oximes. Biochem Pharmacol 2010;80:1427-36
27. Clement JG, Madill HD, Bailey D, et al. Clinical study of a new therapy for nerve agent poisoning: ascending dose tolerance study of HI 6 and atropine. Suffield Report. Defense Research Establishment; Suffield: 1994. p. 1-32
28. Whitley CG, Ngwenya DS. Preotein ligand interactions of 7 halogenated pyridinium salts as inhibitors of acetylcholinesterase from electrophorus electricus. Biochem Mol Biol Int 1995;36:1107-16 (Pubitemid 26176435)
29. Kuca K, Cabal J, Patocka J, et al. Quaternary heteroarenium salts as the competitive inhibitors of the brain acetylcholinesterase. Lett Drug Des Disc 2004;1:97-100
30. Kassa J, Cabal J. A comparison of the efficacy of a new asymmetric bispyridinium oxime BI-6 with presently used oximes and H oximes against sarin by in-vitro and in-vivo methods. Hum Exp Toxicol 1999;18:506-5
31. Kuca K, Kassa J. Oxime induced reactivation of rat brain acetylcholinesterase inhibited by Vx agent. Hum Exp Toxicol 2004;23:167-71 (Pubitemid 38607486)
32. Lorke DE, Kalasz H, Petroianu GA, et al. Entry of oximes into the brain: a review. Curr Med Chem 2008;15:743-53 (Pubitemid 351516790)
33. Bajgar J, Fusek J, Kuca K, et al. Treatment of organophosphate intoxication using cholinesterase reactivators: facts and fiction. Mini Rev Med Chem 2007;7:461-6 (Pubitemid 46845793)
34. Wilson IB, Ginsburg S. Reactivation of alkylphosphate inhibited acetylcholinesterase by bis-quaternary derivatives of 2-PAM and 4-PAM. Biochem Pharmacol 1958;1:200-6
35. Hagedorn I, Stark I, Lorenz HP. Reaktivierung phosphorylierter acetylcholinesterase-abhangigkeit von der aktivator-aciditat. Angew Chem 1972;84:354-6
36. Worek F, Wille T, Koller M, et al. Reactivation kinetics of a series of related bispyridinium oximes with organophosphate-inhibited human acetylcholinesterase-Structure - activity relationships. Biochem Pharmacol 2012;83:1700-6
37. Kassa J, Jun D, Karasova J, et al. A comparison of reactivating efficacy of newly developed oximes (K074, K075) and currently available oximes (obidoxime, HI-6) in soman, cyclosarin and tabun poisoned rats. Chem Biol Interact 2008;175:425-7
38. Pang YP, Kollmeyer TM, Hong F, et al. Rational design of alkylene-linked bispyridiniumaldoximesas improved acetylcholinesterase reactivators. Chem Biol 2003;10:491-502 (Pubitemid 36774636)
39. Acharya J, Gupta AK, Mazumder A, et al. In-vitro regeneration of sarin inhibited electric eel acetylcholinesterase by bis-pyridinium oximes bearing xylene linker. Eur J Med Chem 2009;44:1326-30
40. Musilek K, Holas O, Jun D, et al. Monooxime reactivators of acetylcholinesterase with (E)-but-2-ene linker-Preparation and reactivation of tabun and paraoxon-inhibited acetylcholinesterase. Bioorg Med Chem 2007;15:6733-41 (Pubitemid 47385242)
41. Board on toxicology and environmentalhealth hazards assembly of life sciences: panel on cholinesterase reactivator chemicals PoP, panel of irritants and vesicants: cholinersterase reactivators, psychochemicals and irritants and vesicants. Volume 2 National Academy Press; Washington, DC: 1984
42. Voicu VA, Bajgar J, Medvedovici A, et al. Pharmacokinetics and pharmacodynamics of some oximes and associated therapeutic consequences: a critical review. J Appl Toxicol 2010;30:719-29
43. Voicu VA, Thiermann H, Radulescu FS,et al. The toxicokinetics and toxicodynamics of organophosphonates versus the pharmacokinetics and pharmacodynamics of oxime antidotes: biological consequences. Basic Clin Pharmacol Toxicol 2010;106:73-85
44. Askew BM, Davies DR, Green AL, et al. The nature of the toxicity of 2-oxo-oximes. Br J Pharmacol Chemother 1956;11:424-7
45. Marrs TC. Toxicology of oximes used in treatment of organophosphate poisoning. Adverse Drug React Toxicol Rev 1991;10:61-72
46. Shih TM, Skovira J, O'Donnell J, et al. Treatment with tertiary oximes prevents seizures and improves survival following sarin intoxication. J Mol Neurosci 2010;40:63-9
47. Board on toxicology and environmental health hazards assembly of life sciences: anel on cholinesterase reactivator chemicals PoP, panel of irritants and vesicants: anticholinesterase and anticholinergics. Volume 1 National Academy Press; Washington, DC: 1982
48. Davies DR, Willey GL. The toxicity of 2-hydroxyiminomethyl- N-methylpyridinium methanesulphonate P2S). Br J Pharmacol Chemother 1958;13:202-6
49. Boskovic B, Tadic V, Kusic R. Reactivating and protective effects of Pro-2PAM in mice poisoned with paraoxon. Toxicol Appl Pharmacol 1980;55:32-6 (Pubitemid 10036687)
50. Erdmann WD, Engelhard H. Pharmacologic-toxicologic studies with the dichloride of bis-(4- hydroxyiminomethyl-1-pyridiniummethyl)- ether, a new esterase reactivator. Arzneimittelforschung 1964;14:5-11
51. Musilek K, Dolezal M, Gunn-Moore F, et al. Design, evaluation and structure-activity relationship studies of the AChE reactivators against organophosphorus pesticides. Med Res Rev 2011;31:548-75
52. Dawson RM. Rate constants of carbamylation and decarbamylation of acetylcholinesterase for physostigmine and carbaryl in the presence of an oxime. Neurochem Int 1994;24:173-82 (Pubitemid 24061868)
53. Petroianu GA, Lorke DE, Hasan MY, et al. Paraoxon has only a minimal effect on pralidoxime brain concentration in rats. J Appl Toxicol 2007;27(4):350-35
54. Sakurada K, Matsubara K, Shimizu K, et al. Pralidoxime iodide (2-PAM) penetrates across the blood-brain barrier. Neurochem Res 2003;28:1401-7 (Pubitemid 38113071)
55. Firemark H, Barlow CF, Roth LJ. The penetration of 2-Pam-C14 into brain and the effect of cholinesterase inhibitors onits transport. J Pharmacol Exp Ther 1964;145:252-65
56. Askew BM. Oximes and hydroxamic acids as antidotes in anticholinesterase poisoning. Br J Pharmacol Chemother 1956;11:417-23
57. Eyer P, Kawan A, Ladstetter B. Formation of cyanide after i.v. administration of the oxime HI 6 to dogs. Arch Toxicol 1987;61:63-9 (Pubitemid 17149978)
58. Shih TM, Kan RK, McDonough JH. In vivo cholinesterase inhibitory specificity of organophosphorus nerve agents. Chem Biol Interact 2005;157/158:293-303 (Pubitemid 41757665)
59. Czerwinski SE, Skvorak JP, Maxwell DM, et al. Effect of octanol: water partition coefficients of organophosphorus compounds on biodistribution and percutaneous toxicity. J Biochem Mol Toxicol 2006;20:241-6 (Pubitemid 44569560)
60. Voicu VA, Sakurada K, Ohta K, et al. Biopharmaceutical limitations of oximes and their pharmacodynamic/ toxicodynamic consequences. 13th International Congress of the Romanian Society of Clinical Pharmacology, Therapeutics and Toxicology; Poiana Brasov; 2012
61. Falb A, Erdmann WD. Penetration of 14C-obidoxime through the so-called blood-brain barrier of mice and rats. Arch Toxikol 1969;24:123-32
62. Bajgar J. Differential inhibition of the brain acetylcholinesterase molecular forms following sarin, soman and VX intoxication in laboratory rats. Acta Med (Hradec Kralove) 1997;40:89-94
63. Kassa J. The influence of oxime and anticholinergic drug selection on the potency of antidotal treatment to counteract acute toxic effects of tabun in mice. Neurotox Res 2006;9:59-62
64. Clement JG. Central activity of acetylcholinesterase oxime reactivators. Toxicol Appl Pharmacol 1992;112:104-9
65. Bajgar J, Jakl A, Hrdina V. The influence of obidoxime on acetylcholinesterase activity in different parts of the mouse brain following isopropylmethyl phosphonofluoridate intoxication. Eur J Pharmacol 1972;19:199-202
66. Bajgar J, Patocka J, Jakl A, et al. Antidotal therapy and changes of acetylcholinesterase activity following isopropyl methylphosphonofluoridate intoxication in mice. Acta Biol Med Ger 1975;34:1049-55
67. Bajgar J, Tulach J, Jakl A, et al. Differences in anticholinesterase action of some organophosphorus compounds in vivo. Acta Biol Med Ger 1971;27:171-8
68. Jovanović D. Pharmacokinetics of pralidoxime chloride. Arch Toxicol 1989;63:416-18
69. Maksimovic M, Jovanovic D, Kovacevic V, et al. Oral kinetics and bioavailability of the cholinesterase reactivator HI-6 after administration of 2 different formulations of tablets to dogs. Toxicol Lett 1987;39:85-91 (Pubitemid 17157067)
70. Sundwall A. Minimum concentrations of N-methylpyridinium-2-aldoxime methane sulphonate (P2S) which reverse neuromuscular block. Biochem Pharmacol 1961;8:413-17
71. Kusic R, Jovanovic D, Randjelovic S, et al. HI-6 in man: efficacy of the oxime in poisoning by organophosphorus insecticides. Hum Exp Toxicol 1991;10:113-18
72. Sidell FR, Groff WA, Ellin RI. Bloodlevels of oxime and symptoms in humans after single and multiple oral doses of 2-pyridine aldoxime methochloride. J Pharm Sci 1969;58:1093-8
73. Dawson RM. Review of oximes available for treatment of nerve agent poisoning. J Appl Toxicol 1994;14:317-31 (Pubitemid 24302511)
74. Shiloff JD, Clement JG. Comparison of serum concentrations of the acetylcholinesterase oxime reactivators HI-6, obidoxime, and PAM to efficacy against sarin (isopropyl methylphosphonofluoridate) poisoning in rats. Toxicol Appl Pharmacol 1987;89:278-80 (Pubitemid 17104807)
75. Sidell FR, Groff WA. Toxogonin: blood levels and side effects after intramuscular administration in man. J Pharm Sci 1970;59:793-7
76. Kusic R, Boskovic B, Vojvodic V, et al. HI-6 in man: blood levels, urinary excretion, and tolerance after intramuscular administration of the oxime to healthy volunteers. Fundam Appl Toxicol 1985;5:S89-97 (Pubitemid 16134970)
77. Holland P, Parkes DC. Plasma concentrations of the oxime pralidoxime mesylate (P2S) after repeated oral and intramuscular administration. Br J Ind Med 1976;33:43-6
78. Sidell FR, Groff WA. Intramuscular and intravenous administration of small doses of 2-pyridinium aldoxime methochloride to man. J Pharm Sci 1971;60:1224-8
79. Sidell FR, Groff WA, Kaminskis A. Toxogonin and pralidoxime: kinetic comparison after intravenous administration to man. J Pharm Sci 1972;61:1765-9
80. Sidell FR, Groff WA, Kaminskis A. Pralidoxime methanesulfonate: plasma levels and pharmacokinetics after oral administration to man. J Pharm Sci 1972;61:1136-40
81. Vojvodić VB. Blood levels, urinary excretion and potential toxicity of N, N'-trimethylenebis (pyridinium 4- aldoxime) dichloride (TMB-4) in healthy man following intramuscular injection of the oxime. Eur J Clin Pharmacol 1970;2:216-20
82. Becker C, Worek F, John H.Chromatographic analysis of toxic phosphylated oximes (POX): a brief overview. Drug Test Anal 2010;2:460-8
83. Worek F, Eyer P, Kiderlen D, et al. Effect of human plasma on the reactivation of sarin-inhibited human erythrocyte acetylcholinesterase. Arch Toxicol 2000;74:21-6 (Pubitemid 30207533)
84. Kiderlen D, Eyer P, Worek F. Formation and disposition of diethylphosphoryl-obidoxime, a potent anticholinesterase that is hydrolyzed by human paraoxonase (PON1). Biochem Pharmacol 2005;69:1853-67 (Pubitemid 40780084)
85. Stenzel J, Worek F, Eyer P. Preparation and characterization of dialkylphosphoryl-obidoxime conjugates, potent anticholinesterase derivatives that are quickly hydrolyzed by human paraoxonase (PON1192Q). Biochem Pharmacol 2007;74:1390-400 (Pubitemid 47445445)
86. Luo C, Saxena A, Smith M, et al. Phosphoryl Oxime Inhibition ofAcetylcholinesterase during Oxime Reactivation Is Prevented by Edrophonium. Biochemistry 1999;38:9937-47
87. Wilson IB, Ginsberg S, Meislich EK. The reactivation of acetylcholinesteraseinhibited by tetraethyl pyrophosphate and diisopropyl fluorophosphate.1. J Am Chem Soc 1955;77:4286-91
88. Wilson IB, Meislich EK. Reactivation of acetylcholinesterase inhibited byalkylphosphates. J Am Chem Soc 1953;75:4628-9
89. Kiderlen D, Worek F, Klimmek R, et al. The phosphoryl oxime-destroying activityof human plasma. Arch Toxicol 2000;74:27-32 (Pubitemid 30207534)
90. Ashani Y, Bhattacharjee AK, Leader H, et al. Inhibition of cholinesterases withcationic phosphonyl oximes highlights distinctive properties of the charged yridine groups of quaternary oxime reactivators. Biochem Pharmacol 2003;66:191-202 (Pubitemid 36776393)
91. Radchenko EV, Makhaeva GF, Malygin VV, et al. Modeling of the relationships between the structure of O-phosphorylated oximes and their anticholinesterase activity and selectivity using molecular field topology analysis (MFTA). Dokl Biochem Biophys 2008;418:47-51 (Pubitemid 351399437)
92. Radchenko EV, Makhaeva GF, Sokolov VB, et al. Study of the structural determinants of acute and delayed neurotoxicity of O-phosphorylated oximes by molecular field topology analysis (MFTA). Dokl Biochem Biophys 2009;429:309-14
93. Radchenko EV, Mel'nikov AA, Makhaeva GF, et al. Molecular design of O-phosphorylated oximes - selective inhibitors of butyrylcholinesterase. Dokl Biochem Biophys 2012;443:91-5
94. Eddleston M, Szinicz L, Eyer P, et al. Oximes in acute organophosphorus pesticide poisoning: a systematic review of clinical trials. QJM 2002;95:275-83 (Pubitemid 34546005)
95. Organization WH: Public Health impact of pesticides used in agriculture. Office of Publications, World Health Organization; Geneva, Switzerland: 1990
96. Zilker T. Medical management of incidents with chemical warfare agents. Toxicology 2005;214:221-31 (Pubitemid 41406262)
97. Marrs TC, Rice P, Vale JA. The role of oximes in the treatment of nerve agent poisoning in civilian casualties. Toxicol Rev 2006;25:297-323
98. Worek F, Diepold C, Eyer P. Dimethylphosphoryl-inhibited human cholinesterases: inhibition, reactivation, and aging kinetics. Arch Toxicol 1999;73:7-14 (Pubitemid 29155825)
99. Marrs TC, Vale JA. Chapter 49 -management of organophosphorus pesticide poisoning. In: Ramesh CG, editor. Toxicology of organophosphate & carbamate compounds. Academic Press; Burlington: 2006. p. 715-33
100. Balali-Mood M, Balali-Mood K,Hosseini Shirazic F. Recent advances in treatment of acute organophosphorous nerve agents poisoning. Iranian J Pharm Res 2006;2:79-87
101. Eddleston M, Eyer P, Worek F, et al. Differences between organophosphorus insecticides in human self-poisoning: a prospective cohort study. Lancet 2005;366:1452-9 (Pubitemid 41483811)
102. Eddleston M, Buckley NA, Eyer P, et al. Management of acute organophosphorus pesticide poisoning. Lancet 2008;371:597-607 (Pubitemid 351232010)
103. Eyer P. The role of oximes in the management of organophosphorus pesticide poisoning. Toxicol Rev 2003;22:165-90 (Pubitemid 38659720)
104. Milatović D, Jokanović M. Chapter 65 - pyridinium oximes as cholinesterase reactivators in the treatment of OP poisoning. In: Ramesh CG, editor. Handbook of toxicology of chemical warfare agents. Academic Press; San Diego: 2009. p. 985-96
105. Worek F, Eyer P, Aurbek N, et al. Recent advances in evaluation of oxime efficacy in nerve agent poisoning by in vitro analysis. Toxicol Appl Pharmacol 2007;219(2-3):226-34 (Pubitemid 46282867)
106. Eddleston M, Eyer P, Worek F, et al. Pralidoxime in acute organophosphorus insecticide poisoning - A randomized controlled trial. PLoS Med 2009;6:e1000104
107. Buckley NA, Eddleston M, Li Y, et al. Oximes for acute organophosphate pesticide poisoning. Cochrane Database Syst Rev 2011(2):CD005085
108. Thiermann H, Szinicz L, Eyer P, et al. Correlation between red blood cell acetylcholinesterase activity and neuromuscular transmission in organophosphate poisoning. Chem Biol Interact 2005;157-158:345-7 (Pubitemid 41757673)
109. Thiermann H, Eyer P, Worek F. Muscle force and acetylcholinesterase activity inmouse hemidiaphragms exposed to paraoxon and treated by oximes in vitro. Toxicology 2010;272:46-51
110. Fournier E, Quan DQ, Sonnier M, et al. Reactivation by 1-hydroxyimino-4- methyl-2-pentamone of plasma cholinesterases in the dog inhibited by different orgenophosphates. Eur J oxicol Environ Hyg 1975;8:220-5
111. Ellin RI, Wills JH. Oximes antagonistic to inhibitors of cholinesterase. II.J Pharm Sci 1964;53:1143-50
112. Boskovic B, Kovacevic V, Jovanovic D. PAM-2 Cl, HI-6, and HGG-12 in soman and tabun poisoning. Fundam Appl Toxicol 1984;4:S106-15 (Pubitemid 14005966)
113. Oldiges H, Schoene K. Pyridinium and imidazolium salts as antidotes for soman and paraoxon poisoning in mice. Arch Toxikol 1970;26:293-305
114. Sevelova L, Kuca K, Krejcova-Kunesova G. Antidotal treatment of GF-agent intoxication in mice with bispyridinium oximes. Toxicology 2005;207:1-6 (Pubitemid 39601680)
115. Kepner LA, Wolthuis OL. A comparison of the oximes HS-6 and HI-6 in the therapy of soman intoxication in rodents. Eur J Pharmacol 1978;48:377-82 (Pubitemid 9193576)
116. Clement JG. Efficacy of mono- and bis-pyridinium oximes versus soman, sarin and tabun poisoning in mice. Fundam Appl Toxicol 1983;3:533-5 (Pubitemid 14199842)
117. Clement JG. Effect of fasting on the acute toxicity of HI-6 and its efficacy in soman poisoned mice. Fundam Appl Toxicol 1982;2:88-9
118. Kassa J, Cabal J. A comparison of the efficacy of acetylcholinesterase reactivators against cyclohexyl methylphosphonofluoridate (GF agent) by in vitro and in vivo methods. Pharmacol Toxicol 1999;84(1):41-5 (Pubitemid 29069238)
119. Fleisher JH, Harris LW, Miller GR,et al. Antagonism of sarin poisoning in rats and guinea pigs by atropine, oximes, and mecamylamine. Toxicol Appl Pharmacol 1970;16:40-7
120. Donzanti BA, Green MD, Shores EL. Atropine sulfate and 2-pyridine aldoxime methylchloride elicit stress-induced convulsions and lethality in mice and guinea pigs. Drug Chem Toxicol 1985;8:431-49 (Pubitemid 16164340)
121. O'Leary JF, Kunkel AM, Jones AH. Efficacy and limitations of oxime-atropine treatment of organophosphorus anticholinesterase poisoning. J Pharmacol Exp Ther 1961;132:50-7
122. Engelhard N Erdmann WD. The interrelation of chemical structure cholinesterase reactivating effect in a Series Of New Bis-quaternary Pyridine-4-aldoximes. Arzneimittelforschung 1964;14870-5
123. Durham WF, Hayes WJ Jr. Organic phosphorus poisoning and its therapy. With special reference to modes of action and compounds that reactivate inhibited cholinesterase. Arch Environ Health 1962;5:21-47
124. Fleisher JH, Michel HO, Yates L, et al. 1,1'-Trimethylene bis(4- formylpyridinium bromide) dioxime (TMB-4) and 2-pyridine aldoxime methiodide (2-PAM) as adjuvants to atropine in the treatment of anticholinesterase poisoning. J Pharmacol Exp Ther 1960;129:31-5
125. Clement JG, Shiloff JD, Gennings C. Efficacy of a combination of acetylcholinesterase reactivators, HI-6 and obidoxime, against tabun and soman poisoning of mice. Arch Toxicol 1987;61:70-5 (Pubitemid 17149979)
126. Cassel G, Karlsson L, Waara L, et al.Pharmacokinetics and effects of HI-6 in blood and brain of soman-intoxicated rats: a microdialysis study. Eur J Pharmacol 1997;332:43-52 (Pubitemid 27346602)
127. Lukey BJ, Woodard CL, Clark CR, et al. HI-6 pharmacokinetics in rabbits after intravenous and intramuscular administration. J Pharm Pharmacol 1992;44:690-2
128. Woodard CL, Lukey BJ. MMB-4 pharmacokinetics in rabbits after intravenous and intramuscular administration. Drug Metab Dispos 1991;19:283-4